Molecular Genetics of HNPCC

HNPCC 的分子遗传学

基本信息

  • 批准号:
    6633111
  • 负责人:
  • 金额:
    $ 43.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-06-01 至 2006-05-31
  • 项目状态:
    已结题

项目摘要

The overall goal of this proposal is to build upon and expand our unique clinical and specimen resource of hereditary non-polyposis colorectal cancer (HNPCC) patients to further elucidate genetic and epigenetic factors associated with increased risk for HNPCC. Epidemiologic data will be obtained on 400 subjects carrying germline mutations in either the hMSH2 or hMLH1 gene. It is hypothesized that genes playing minor roles in risk of cancer, modifier genes, are important in predicting risk of colorectal cancer in HNPCC. Polymorphisms in cell cycle genes such as cyclin D1, p53, and p21, will be studied to determine if they influence age of onset in HNPCC. Environmental factors, particularly those involving the folate pathway and heterocyclic amines intake will be studied to determine if they are associated with risk of HNPCC. Polymorphisms in metabolic genes such as N- Acetyltransferase 1 (NAT1), N-Acetyltransferase 2 (NAT2), Glutathione S-transferase M1 (GSTM1), Glutathione S-transferase T1 (GSTT1), will be studied to determine if they influence age of onset of HNPCC, and then to determine if any of the four genes, in combination with dietary intake data (with emphasis on heterocyclic amines) influence age of onset in HNPCC. A polymorphism of the Methylene tetrahydrofolate reductase (MTHFR) gene at codon 677 will be studied to determine if it influences age of onset of HNPCC, and then to determine in combination with dietary intake data (with emphasis on folate) if it influence age of onset of HNPCC. Models will be developed to predict i) the risk that an individual with MMR mutation will develop specific cancers and ii) the probability that a CRC patient will have a MMR mutation given the age at onset, MSI status (where known), and family history. For the first type of model, we will use the newly developed kin-cohort approach. To predict the probability that an individual is a mutation carrier, we will apply logistic regression and Classification and Regression Trees (CART). This will be the first large systematic study on the roles of modifier genes in HNPCC. The proposed studies will provide important information regarding underlying genetic and epigenetic factors involved in colorectal carcinogenesis in HNPCC and has the potential to provide novel insights into the molecular pathways that might influence this process.
本提案的总体目标是建立和扩大我们独特的遗传性非息肉性结直肠癌(HNPCC)患者的临床和标本资源,以进一步阐明与HNPCC风险增加相关的遗传和表观遗传因素。将获得400名携带hMSH2或hMLH1基因种系突变的受试者的流行病学数据。我们推测,在癌症风险中起次要作用的基因,即修饰基因,在预测HNPCC患者结直肠癌风险中起重要作用。细胞周期基因如细胞周期蛋白D1、p53和p21的多态性将被研究,以确定它们是否影响HNPCC的发病年龄。将研究环境因素,特别是涉及叶酸途径和杂环胺摄入的环境因素,以确定它们是否与HNPCC的风险相关。研究代谢基因如N-乙酰转移酶1 (NAT1)、N-乙酰转移酶2 (NAT2)、谷胱甘肽s -转移酶M1 (GSTM1)、谷胱甘肽s -转移酶T1 (GSTT1)的多态性,以确定它们是否影响HNPCC的发病年龄,然后确定这四种基因中的任何一种,结合饮食摄入数据(重点是杂环胺)影响HNPCC的发病年龄。将研究密码子677处亚甲基四氢叶酸还原酶(MTHFR)基因的多态性,以确定它是否影响HNPCC的发病年龄,然后结合饮食摄入数据(重点是叶酸)确定它是否影响HNPCC的发病年龄。将建立模型来预测i) MMR突变个体发展为特定癌症的风险;ii)考虑到发病年龄、MSI状态(已知的)和家族史,CRC患者发生MMR突变的概率。对于第一种模型,我们将使用新开发的亲属队列方法。为了预测个体是突变携带者的概率,我们将应用逻辑回归和分类回归树(CART)。这将是第一个关于修饰基因在HNPCC中作用的大型系统研究。拟议的研究将提供有关HNPCC中参与结直肠癌发生的潜在遗传和表观遗传因素的重要信息,并有可能为可能影响这一过程的分子途径提供新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARSHA L. FRAZIER其他文献

MARSHA L. FRAZIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARSHA L. FRAZIER', 18)}}的其他基金

Biospecimen Extraction
生物样本提取
  • 批准号:
    7695930
  • 财政年份:
    2008
  • 资助金额:
    $ 43.97万
  • 项目类别:
Mouse Model of Pancreatic Tumorigenesis with Dysregulation of mTOR
mTOR 失调的小鼠胰腺肿瘤发生模型
  • 批准号:
    7535942
  • 财政年份:
    2008
  • 资助金额:
    $ 43.97万
  • 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
  • 批准号:
    8289475
  • 财政年份:
    2004
  • 资助金额:
    $ 43.97万
  • 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
  • 批准号:
    8515943
  • 财政年份:
    2004
  • 资助金额:
    $ 43.97万
  • 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
  • 批准号:
    7983177
  • 财政年份:
    2004
  • 资助金额:
    $ 43.97万
  • 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
  • 批准号:
    8130791
  • 财政年份:
    2004
  • 资助金额:
    $ 43.97万
  • 项目类别:
MOUSE MODEL FOR THE PEUTZ JEGHERS SYNDROME
黑息综合症小鼠模型
  • 批准号:
    6489438
  • 财政年份:
    2001
  • 资助金额:
    $ 43.97万
  • 项目类别:
CORE--NUCLEIC ACID FACILITY
核心--核酸设施
  • 批准号:
    6481862
  • 财政年份:
    2001
  • 资助金额:
    $ 43.97万
  • 项目类别:
MOUSE MODEL FOR THE PEUTZ JEGHERS SYNDROME
黑息综合症小鼠模型
  • 批准号:
    6292089
  • 财政年份:
    2001
  • 资助金额:
    $ 43.97万
  • 项目类别:
CORE--NUCLEIC ACID FACILITY
核心--核酸设施
  • 批准号:
    6352707
  • 财政年份:
    2000
  • 资助金额:
    $ 43.97万
  • 项目类别:

相似海外基金

Urinary Phthalate Biomarker Concentrations and Breast and Prostate Cancer Risk in a National Cohort of Adults in Canada
加拿大全国成人队列中尿液邻苯二甲酸盐生物标志物浓度与乳腺癌和前列腺癌风险
  • 批准号:
    494953
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
    Operating Grants
Prospective metabolomics investigation of gastric cancer risk in African Americans and European Whites with a low socioeconomic status
社会经济地位较低的非裔美国人和欧洲白人胃癌风险的前瞻性代谢组学调查
  • 批准号:
    10912190
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders
深度学习图像分析算法可改善口腔潜在恶性疾病的口腔癌风险评估
  • 批准号:
    10805177
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Developing diagnostics of patient-specific cancer risk and early-stage tumorigenesis
开发患者特异性癌症风险和早期肿瘤发生的诊断方法
  • 批准号:
    478999
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
    Operating Grants
Environmental Metal Exposures and Breast Cancer Risk: A Prospective Study of Nationally Representative Canadian Data
环境金属暴露与乳腺癌风险:加拿大全国代表性数据的前瞻性研究
  • 批准号:
    495159
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Mechanisms of tamoxifen-associated endometrial cancer risk
他莫昔芬相关子宫内膜癌风险的机制
  • 批准号:
    10650054
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Gut microbiota-related mechanisms that impact colorectal cancer risk after bariatric surgery
影响减肥手术后结直肠癌风险的肠道微生物相关机制
  • 批准号:
    10733566
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Obesity, body fat distribution, and breast cancer risk: is visceral fat the culprit after menopause?
肥胖、身体脂肪分布和乳腺癌风险:内脏脂肪是绝经后的罪魁祸首吗?
  • 批准号:
    10586626
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
Optimization of a personalized skin cancer risk intervention for at-risk young adults
针对高危年轻人的个性化皮肤癌风险干预措施的优化
  • 批准号:
    10582944
  • 财政年份:
    2023
  • 资助金额:
    $ 43.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了